Celosia Therapeutics has begun dosing the first participant in its Phase 1b KOANEWA trial to test CTx1000, a genetic medicine aimed at clearing pathological TDP-43 protein in ALS patients. This trial, conducted at Macquarie University Hospital, focuses on safety and tolerability while exploring potential efficacy in modifying ALS progression. CTx1000 is based on a discovery identifying a binder to TDP-43, which in preclinical models halted and partially reversed ALS symptoms. This marks a significant step toward a potential new treatment for this fatal neurodegenerative disease.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
AmpliTech Group marked its fifth anniversary as a public company by ringing the Nasdaq opening bell and announcing record revenue of $25.2 million in fiscal 2025, a 165% increase year-over-year. The company, a US-based leader in RF and microwave sign...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
